Novartis to present first of its kind evidence for Cosentyx® on potential to maintain mobility in patients with AS and PsA
(Thomson Reuters ONE) -
Novartis International AG /
Novartis to present first of its kind evidence for Cosentyx® on potential to
maintain mobility in patients with AS and PsA
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Long-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in
psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual
Meeting[1],[2]
* Structural disease progression is a major concern for AS and PsA patients as
it may prompt mobility loss[3] - new data to provide further evidence on the
efficacy of Cosentyx to reduce structural disease progression
* Cosentyx is the first and only IL-17A inhibitor approved for AS and PsA as
well as psoriasis, and has been used by more than 100,000 patients across
indications worldwide[4]
The digital press release with multimedia content can be accessed here:
Basel, October 30, 2017 - New evidence on the efficacy of the innovative
biologic Cosentyx(®) (secukinumab) demonstrating its potential to reduce
structural disease progression in patients with specific rheumatological
conditions will be presented at the 2017 ACR/ARHP Annual Meeting in San Diego,
United States. The Cosentyx late breaking presentations will include new 4-year
data from the MEASURE 1 study in patients with ankylosing spondylitis (AS), and
24-week data from the FUTURE 5 study in patients with psoriatic arthritis (PsA),
two debilitating autoimmune diseases with a high risk of mobility loss.
"Maintaining mobility is our hope and vision for every patient with chronic
inflammatory diseases such as AS and PsA." said Vas Narasimhan, Global Head,
Drug Development and Chief Medical Officer, Novartis. "Reducing radiographic
progression would be a strong signal for patients who hope to stay mobile as
this would result in a significant improvement of their quality of life."
Cosentyx is a fully-human, targeted biologic approved for patients with AS, PsA,
or psoriasis (PsO). Cosentyx is the first and only fully human monoclonal
antibody that selectively neutralizes interleukin-17A (IL-17A), the key cytokine
involved in the pathogenesis of AS, PsA and PsO[5]-[7]. Today, Cosentyx has been
used by more than 100,000 patients worldwide[4]. Across all three indications,
Cosentyx has demonstrated rapid and sustained efficacy as well as a consistently
favorable safety profile[1],[2],[8], including close to zero injection site
reactions or associated pain[9],[10].
About Cosentyx and IL-17A
Cosentyx is the first and only IL-17A inhibitor approved to treat ankylosing
spondylitis (AS) and psoriatic arthritis (PsA), two autoimmune diseases in
rheumatology, as well as psoriasis[5]. Cosentyx is a fully-human, targeted
biologic that specifically inhibits the IL-17A cytokine which plays a
significant role in the pathogenesis of AS, PsA and plaque psoriasis[5]-[7]. IL-
17A is a key cytokine involved in the inflammation of the entheses - the sites
where tendons or ligaments connect to the bone[11]-[13].
Cosentyx is the first IL-17A inhibitor approved in more than 70 countries for
the treatment of active AS and PsA, which includes the European Union countries
and the US. Cosentyx is also approved for the treatment of PsA and pustular
psoriasis in Japan[4].
Cosentyx is also approved in more than 75 countries for the treatment of
moderate-to-severe plaque psoriasis, which includes the European Union
countries, Japan, Switzerland, Australia, the US and Canada. In Europe, Cosentyx
is approved for the first-line systemic treatment of moderate-to-severe plaque
psoriasis in adult patients. In the US, Cosentyx is approved as a treatment for
moderate-to-severe plaque psoriasis in adult patients who are candidates for
systemic therapy or phototherapy (light therapy)[14].
Cosentyx has a proven safety profile with close to zero injection site reactions
or injection site associated pain[9],[10].
About ankylosing spondylitis (AS) and psoriatic arthritis (PsA)
Ankylosing spondylitis (AS) is part of a family of life-long inflammatory
diseases, which also includes psoriatic arthritis (PsA). AS is characterized by
inflammation of the sacroiliac joints and new bone formation caused by increased
levels of IL-17A, with severe cases progressing to irreversible spinal
fusion[12],[15]. AS can cause serious impairment of movement in the spine and
physical function, which has an impact on quality of life. People in their teens
and twenties, particularly males, are affected most often[16],[17].
PsA is a debilitating autoimmune diseases with a high risk of mobility loss.
Symptoms of PsA include joint pain and stiffness, skin and nail psoriasis,
swollen toes and fingers, persistent painful swelling of the tendons, and
irreversible joint damage[18]. Up to 40% of people can suffer from joint
destruction and permanent physical deformity[19].
IL-17A plays a significant role in disease pathogenesis of AS, PsA and plaque
psoriasis, which is significant as up to 30 of psoriasis patients will develop
PsA during their lifetime[18] and as many as 1 in 4 people with psoriasis may
have undiagnosed PsA[20].
About the MEASURE 1 study
MEASURE 1 is a 2-year, multicenter, randomized, placebo-controlled Phase III
study assessing the efficacy and safety of Cosentyx in patients with active AS.
A total of 290 of 371 patients completed the trial, after which 274 patients
were invited to enter a 3-year extension period[1],[21]. Primary endpoints
assessed superiority of Cosentyx against placebo at Week 16 in the proportion of
patients achieving at least a 20% improvement in the ASAS 20 response
criteria[1],[22]. From Week 16, patients in the placebo arm of the study were
re-randomized to Cosentyx 75 mg or 150 mg based on ASAS 20 response, with non-
responders switched at Week 16, and responders at Week 24[1],[22]. In total,
83/87 and 95/100 patients who enrolled in the extension and randomized to
Cosentyx 75 mg and 150 mg respectively completed 156 weeks[1].
About the FUTURE 5 study[2]
In the study, participants (n=996) with active PsA were randomized to receive
Cosentyx at 300 mg with loading dose (LD), 150 mg with LD, 150 mg without LD, or
placebo. All groups received Cosentyx or placebo at baseline (BL), weeks
1, 2, 3, and 4, and then every 4 weeks. At week 16, placebo non-responders
(patients with <20% improvement from BL in tender or swollen joint counts) were
switched to Cosentyx 300 mg or 150 mg; remaining placebo patients were switched
at week 24. The primary endpoint was ACR20 at week 16 and the key secondary
endpoint was radiographic structural progression, as measured by mTSS, assessed
by two blinded readers, based on hand/wrist/foot X-rays obtained at BL, week 16
(non-responders), and week 24. With nearly 1,000 patients included in the Phase
III study, FUTURE 5 is the largest randomized controlled trial (RCT) of a
biologic conducted in PsA.
Disclaimer
This press release contains forward-looking statements within the meaning of the
United States Private Securities Litigation Reform Act of 1995. Forward-looking
statements can generally be identified by words such as "potential," "can,"
"will," "plan," "expect," "anticipate," "look forward," "believe," "committed,"
"investigational," "pipeline," "launch," or similar terms, or by express or
implied discussions regarding potential marketing approvals, new indications or
labeling for the investigational or approved products described in this press
release, or regarding potential future revenues from such products. You should
not place undue reliance on these statements. Such forward-looking statements
are based on our current beliefs and expectations regarding future events, and
are subject to significant known and unknown risks and uncertainties. Should one
or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from those set
forth in the forward-looking statements. There can be no guarantee that the
investigational or approved products described in this press release will be
submitted or approved for sale or for any additional indications or labeling in
any market, or at any particular time. Nor can there be any guarantee that such
products will be commercially successful in the future. In particular, our
expectations regarding such products could be affected by, among other things,
the uncertainties inherent in research and development, including clinical trial
results and additional analysis of existing clinical data; regulatory actions or
delays or government regulation generally; our ability to obtain or maintain
proprietary intellectual property protection; the particular prescribing
preferences of physicians and patients; global trends toward health care cost
containment, including government, payor and general public pricing and
reimbursement pressures; general economic and industry conditions, including the
effects of the persistently weak economic and financial environment in many
countries; safety, quality or manufacturing issues, and other risks and factors
referred to in Novartis AG's current Form 20-F on file with the US Securities
and Exchange Commission. Novartis is providing the information in this press
release as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has
leading positions globally in each of these areas. In 2016, the Group achieved
net sales of USD 48.5 billion, while R&D throughout the Group amounted to
approximately USD 9.0 billion. Novartis Group companies employ approximately
121,000 full-time-equivalent associates. Novartis products are sold in
approximately 155 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-
library
For questions about the site or required registration, please contact
media.relations(at)novartis.com
References
[1] Braun J et al. Secukinumab demonstrates low radiographic progression and
sustained efficacy through 4 years in patients with active ankylosing
spondylitis. Presented as a late-breaker at the Annual Meeting of the American
College of Rheumatology. November 7, 2017.
[2] Mease P et al. Subcutaneous Secukinumab Inhibits Radiographic Progression in
Psoriatic Arthritis: Primary Results from a Large Randomized, Controlled,
Double-Blind Phase 3 Study. Presented as a late-breaker at the Annual Meeting of
the American College of Rheumatology. November 7, 2017.
[3] Dougados M et al. Spondyloarthritis. The Lancet. 2011;377:2127-37.
[4] Novartis, data on file.
[5] Cosentyx Summary of Product Characteristics. Novartis Europharm Limited.
Available at:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/
003729/human_med_001832.jsp&mid=WC0b01ac058001d124. Last accessed October 2017
[6] Nestle FO et al. Mechanisms of disease psoriasis. New England Journal of
Medicine. 2009;361:496-509
[7] Girolomoni G et al. Psoriasis: rationale for targeting interleukin-17.
British Journal of Dermatology. 2012;167:717-24.
[8] Bissonnette R et al. Secukinumab demonstrates high sustained efficacy and a
favorable safety profile through 5 years of treatment in moderate to severe
psoriasis. Presented as eposter P2223 at 26th EADV Congress 2017. September
13, 2017.
[9] Reich K et al. Secukinumab, a fully human anti-interleukin-17A monoclonal
antibody, exhibits minimal immunogenicity in patients with moderate-to-severe
plaque psoriasis. British Journal of Dermatology. 2017;176:752-58.
[10] Bissonnette R et al. Secukinumab Sustains Good Efficacy and Favourable
Safety in Moderate to Severe Psoriasis up to 3 Years of Treatment: Results from
A Double-Blind Extension Study. British Journal of Dermatol. 2017 Jun 5. doi:
10.1111/bjd.15706
[11] Kopf M et al. Averting inflammation by targeting the cytokine environment.
Nature Reviews Drug Discovery. 2010;9:703-18.
[12] Onishi RM et al. Interleukin-17 and its target genes: mechanisms of
interleukin-17 function in disease. Immunology. 2010;129:311-21.
[13] Smith JA et al. Review: The Interleukin 23/Interleukin 17 Axis in
Spondyloarthritis Pathogenesis: Th17 and Beyond. Arthritis & Rheumatology.
2014;66:231-41.
[14] Cosentyx (secukinumab) [prescribing information]. East Hanover, NJ:
Novartis Pharmaceuticals Corp, 2016.
[15] Ward MM et al. American College of Rheumatology/Spondylitis Association of
America/Spondyloarthritis Research and Treatment Network 2015 Recommendations
for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial
Spondyloarthritis. Arthritis Care & Research. 2016:68:151-166.
[16] Dean LE et al. Global prevalence of ankylosing spondylitis. Rheumatology
(Oxford). 2014; 53(4):650-7.
[17] American College of Rheumatology (ACR) website. Spondyloarthritis.
Available at: http://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-
Conditions/Spondyloarthritis. Last accessed October 2017.
[18] Mease PJ et al. Managing patients with psoriatic disease: the diagnosis and
pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs
2014; 74:423-41.
[19] Anwar AH, Diamond H. Psoriatic arthritis: practice essentials, background,
pathophysiology and etiology. Medscape reference website. Available at:
http://emedicine.medscape.com/article/2196539-overview#a6. Last accessed October
2017.
[20] National Psoriasis Foundation. Could You Have Psoriatic Arthritis? Know the
Signs. Available at https://www.psoriasis.org/psoriatic-arthritis/know-the-
signs. Last accessed October 2017.
[21] Baraliakos X et al. Secukinumab provides sustained improvements in the
signs and symptoms of active ankylosing spondylitis: 3-year results from a phase
3 extension trial (MEASURE 1). Presented at the Annual European Congress of
Rheumatology (EULAR 2017). 15(th) June 2017.
[22] Braun J et al. Effect of secukinumab on clinical and radiographic outcomes
in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE
1 study. Annals of the Rheumatic Diseases
2016;doi: 10.1136/annrheumdis-2016-209730.
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations(at)novartis.com
Eric Althoff Friedrich von Heyl
Novartis Global Media Relations Novartis Global Pharma Communications
+41 61 324 7999 (direct) +41 61 324 8984 (direct)
+41 79 593 4202 (mobile) +41 79 749 0286 (mobile)
eric.althoff(at)novartis.com friedrich.vonheyl(at)novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations(at)novartis.com
Central North America
Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448
Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188
Media release (PDF):
http://hugin.info/134323/R/2145502/822470.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Scorpio Gold Produces 4,935 Ounces of Gold in Third Quarter 2017 at the Mineral Ridge Operation, NevadaDatum: 30.10.2017 - 07:15 Uhr
Sprache: Deutsch
News-ID 565699
Anzahl Zeichen: 17771
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 303 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis to present first of its kind evidence for Cosentyx® on potential to maintain mobility in patients with AS and PsA"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
